Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors

Cancer. 1989 Nov 1;64(9):1829-32. doi: 10.1002/1097-0142(19891101)64:9<1829::aid-cncr2820640912>3.0.co;2-g.

Abstract

Eight patients with high-risk gestational trophoblastic tumors (GTT) resistant to multiagent chemotherapy were treated with the combination of cisplatin, vinblastine, and bleomycin (PVB). All patients had a metastatic disease including three patients with two metastatic sites and two patients with brain metastases. Four patients achieved complete remission (CR) with the PVB regimen (50%). Three additional patients had partial remission (PR) of whom two were converted into CR by surgery of resistant residual lesions. One patient relapsed and the remaining five patients in CR were cured (62%). A multimodal approach was necessary in most patients as five of them had hysterectomy and two patients had a whole-brain irradiation. Toxicity was mild with no treatment related deaths.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / secondary
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Female
  • Humans
  • Hysterectomy
  • Pregnancy
  • Remission Induction
  • Trophoblastic Neoplasms / drug therapy*
  • Trophoblastic Neoplasms / secondary
  • Uterine Neoplasms / drug therapy*
  • Vinblastine / administration & dosage

Substances

  • Bleomycin
  • Vinblastine
  • Cisplatin

Supplementary concepts

  • PVB protocol